uman albumin 200g/l solution for infusion (100ml vial)
kedrion s.p.a loc. ai conti, 55051 castelvecchio pascoli, barga - lucca, italy - albumin, human - solution for infusion - albumin, human 20 g/100ml - blood substitutes and perfusion solutions
human albumin takeda 200 mgml solution for infusion
takeda israel ltd - albumin human - solution for infusion - albumin human 200 mg / 1 ml - albumin - restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated and use of a colloid is appropriate.
human albumin takeda 50 mgml solution for infusion
takeda israel ltd - albumin human - solution for infusion - albumin human 50 mg / 1 ml - albumin - restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated and use of a colloid is appropriate.
albumin (human) 5% solution
baxter ag - albumin (human) - solution - 5% - albumin (human) 5% - blood derivatives
albumin (human) 25% solution
baxter ag - albumin (human) - solution - 25% - albumin (human) 25% - blood derivatives
human albumin baxalta 50 g/l inf. sol. i.v. vial
baxalta innovations gmbh - albumin human 50 g/l - solution for infusion - 50 g/l - albumin human 50 mg/ml - albumin
human albumin csl behring 200 g/l inf. sol. i.v. vial
csl behring gmbh - albumin human 200 g/l - solution for infusion - 200 g/l - albumin human 200 g/l - albumin
human albumin csl behring 200 g/l inf. sol. i.v. vial
csl behring gmbh - albumin human 200 g/l - solution for infusion - 200 g/l - albumin human 200 g/l - albumin
proteinuria drops 2053- proteinuria drops liquid
professional complementary health formulas - berberis vulgaris 6x equisetum arvense 6x kidney 6x, 12x ledum palustre 12x phosphorus 12x albumin 12x, 30x - for the temporary relief of mild pain in the back or abdomen, bloating, foaming urine, or swelling of small joints.* *claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated.
recombinate- antihemophilic factor recombinant
baxter healthcare corporation - antihemophilic factor, human recombinant (unii: p89dr4ny54) (antihemophilic factor, human recombinant - unii:p89dr4ny54) - the use of recombinate [antihemophilic factor (recombinant)] is indicated in hemophilia a (classical hemophilia) for the prevention and control of hemorrhagic episodes.2 recombinate is also indicated in the perioperative management of patients with hemophilia a (classical hemophilia). recombinate can be of therapeutic value in patients with acquired factor viii inhibitors not exceeding 10 bethesda units per ml.3 in clinical studies with recombinate, patients with inhibitors who were entered into the previously treated patient trial and those previously untreated children who have developed inhibitor activity on study, showed clinical hemostatic response when the titer of inhibitor was less than 10 bethesda units per ml. however, in such uses, the dosage of recombinate should be controlled by frequent laboratory determinations of circulating factor viii levels as well as the clinical status of the patient. recombinate is not indicated in von willebrand’s disease. recombinate is contraindicated in patients w